Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey - PubMed (original) (raw)
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey
C Pifl et al. Neuroscience. 1991.
Abstract
In an attempt to define neurochemically the part played by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a potential Parkinson's disease-inducing neurotoxin, we measured the tissue concentrations of the monoamines dopamine, noradrenaline and serotonin in 45 brain regions in nine rhesus monkeys (Macaca mulatta) receiving repeated intramuscular injections of a total amount of 2.1-7.5 mg/kg MPTP-HCl. Four monkeys treated with MPTP during a period of one to five weeks developed permanent Parkinsonism, and five animals receiving the neurotoxin during a period of two to seven months remained asymptomatic. We found that, compared with the distribution pattern established in the brain of seven normal (drug-free) rhesus monkeys, in the MPTP-treated monkeys none of the three major brain monoamine neuron systems was completely resistant to the neurotoxin. In addition, each brain monoamine had a characteristic regional pattern of MPTP-induced changes. As expected, the most significant alterations were found within the nigrostriatal dopamine system, i.e. profound dopamine loss in caudate nucleus, putamen and substantia nigra. However, many extrastriatal regions of the subcortex and brainstem also suffered significant loss of dopamine, with the noradrenaline loss in the regionally subdivided brainstem being less widespread, and the serotonin levels least affected. Thus, in subcortex/brainstem the ranking order of sensitivity to MPTP was: dopamine greater than noradrenaline much greater than serotonin. In the cerebral (neo- and limbic) cortex, all three monoamine neuron systems suffered widespread statistically significant losses. The ranking order of MPTP sensitivity of the cortical monoamines was: noradrenaline greater than serotonin greater than dopamine. In the cerebellar cortex, dopamine and noradrenaline concentrations were significantly reduced, whereas the serotonin level remained unchanged. A remarkable observation was that many of the subcortical and cortical changes found in the symptomatic monkeys were also found in the asymptomatic animals. Our data are compatible with several possible mechanisms by which MPTP may have produced the observed patterns of monoamine loss in the brain of the rhesus monkey. Our study demonstrates that in the rhesus monkey MPTP mimicked, in addition to the profound striatal dopamine loss, some of the extrastriatal dopamine, noradrenaline and serotonin changes often seen in the brain of patients with idiopathic Parkinson's disease. However, using our treatment regimen, we have not been able to reproduce in the rhesus monkey the inter-regional pattern of striatal dopamine loss typical of idiopathic Parkinson's disease, i.e. a significantly greater loss of dopamine in the putamen compared with the caudate nucleus.
Similar articles
- The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
Pifl C, Schingnitz G, Hornykiewicz O. Pifl C, et al. Neurosci Lett. 1988 Oct 5;92(2):228-33. doi: 10.1016/0304-3940(88)90066-3. Neurosci Lett. 1988. PMID: 3263594 - Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
Oiwa Y, Eberling JL, Nagy D, Pivirotto P, Emborg ME, Bankiewicz KS. Oiwa Y, et al. Front Biosci. 2003 Sep 1;8:a155-66. doi: 10.2741/1104. Front Biosci. 2003. PMID: 12957824 - Effect of MPTP on Serotonergic Neuronal Systems and Mitochondrial Complex I Activity in the Living Brain: A PET Study on Conscious Rhesus Monkeys.
Kanazawa M, Ohba H, Nishiyama S, Kakiuchi T, Tsukada H. Kanazawa M, et al. J Nucl Med. 2017 Jul;58(7):1111-1116. doi: 10.2967/jnumed.116.189159. Epub 2017 Mar 9. J Nucl Med. 2017. PMID: 28280215 - The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P, Marsden CD. Jenner P, et al. J Neural Transm Suppl. 1986;20:11-39. J Neural Transm Suppl. 1986. PMID: 3091760 Review. - Subclinical damage to the nigrostriatal dopamine system by MPTP as a model of preclinical Parkinson's disease: a review.
Burns RS. Burns RS. Acta Neurol Scand Suppl. 1991;136:29-36. doi: 10.1111/j.1600-0404.1991.tb05017.x. Acta Neurol Scand Suppl. 1991. PMID: 1801534 Review.
Cited by
- Dysfunction of motor cortices in Parkinson's disease.
Chu HY, Smith Y, Lytton WW, Grafton S, Villalba R, Masilamoni G, Wichmann T. Chu HY, et al. Cereb Cortex. 2024 Jul 3;34(7):bhae294. doi: 10.1093/cercor/bhae294. Cereb Cortex. 2024. PMID: 39066504 Free PMC article. Review. - Dose-Ranging Effects of the Intracerebral Administration of Atsttrin in Experimental Model of Parkinson's Disease Induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Mice.
Poniatowski ŁA, Joniec-Maciejak I, Wawer A, Sznejder-Pachołek A, Machaj E, Ziętal K, Mirowska-Guzel D. Poniatowski ŁA, et al. Mol Neurobiol. 2024 Nov;61(11):9432-9458. doi: 10.1007/s12035-024-04161-0. Epub 2024 Apr 20. Mol Neurobiol. 2024. PMID: 38642286 - Transient dystonia correlates with parkinsonism after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in nonhuman primates.
Norris SA, Tian L, Williams EL, Perlmutter JS. Norris SA, et al. Dystonia. 2023;2:11019. doi: 10.3389/dyst.2023.11019. Epub 2023 Feb 1. Dystonia. 2023. PMID: 37711667 Free PMC article. - Overlapping and Distinct Features of Cardiac Pathology in Inherited Human and Murine Ether Lipid Deficiency.
Dorninger F, Kiss A, Rothauer P, Stiglbauer-Tscholakoff A, Kummer S, Fallatah W, Perera-Gonzalez M, Hamza O, König T, Bober MB, Cavallé-Garrido T, Braverman NE, Forss-Petter S, Pifl C, Bauer J, Bittner RE, Helbich TH, Podesser BK, Todt H, Berger J. Dorninger F, et al. Int J Mol Sci. 2023 Jan 18;24(3):1884. doi: 10.3390/ijms24031884. Int J Mol Sci. 2023. PMID: 36768204 Free PMC article. - Oscillatory waveform sharpness asymmetry changes in motor thalamus and motor cortex in a rat model of Parkinson's disease.
Parr-Brownlie LC, Itoga CA, Walters JR, Underwood CF. Parr-Brownlie LC, et al. Exp Neurol. 2022 Aug;354:114089. doi: 10.1016/j.expneurol.2022.114089. Epub 2022 Apr 22. Exp Neurol. 2022. PMID: 35461830 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials